Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RDQ Validation for GERD Diagnosis with Esomeprazole
NCT00291746Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, single-blind, single-arm trial of esomeprazole in gastroesophageal reflux disease (GERD), sponsored by AstraZeneca. Primary endpoints: Selection of Reflux Disease Questionnaire items, Presence/absence of GERD as assessed by endoscopic Los Angeles (LA) grade and 3 more. Started Sep 2005; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00291746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291746.